Egalet (EGLT) Tops Q4 EPS by 41c, Beats on Revenues

Note: EPS may not be comparable

Egalet (NASDAQ: EGLT) reported Q4 EPS of $0.03, $0.41 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $7.8 million versus the consensus estimate of $7.59 million.

• Net Income (Loss): Net loss for the year ended December 31, 2017 was $69.4 million, or $2.05 per share, compared to a net loss of $90.6 million, or $3.70 per share, for the year ended December 31, 2016. Net income for the quarter ended December 31, 2017 was $1.5 million, or $0.03 per share, compared to a net loss of $21.4 million, or $0.87 per share, for the quarter ended December 31, 2016. The net income for the fourth quarter 2017 was primarily driven by the $13.2 million gain on the extinguishment of the debt associated with the 5.50% convertible notes exchanged in December 2017.
• Net Product Sales: There were net product sales of $26.1 million for the year ended December 31, 2017 compared to $16.9 million for the year ended December 31, 2016. There were net product sales of $7.8 million for the quarter ended December 31, 2017 compared to $6.1 million for the same period in 2016. The increase in both periods was due to continued growth in SPRIX Nasal Spray and OXAYDO sales and the fact that ARYMO ER was launched at the end of the first quarter of 2017.

For earnings history and earnings-related data on Egalet (EGLT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c